‘Hit-and-run’ gene therapy nanoparticles could enhance CAR-T treatments – FierceBiotech
FierceBiotech |
'Hit-and-run' gene therapy nanoparticles could enhance CAR–T treatments
FierceBiotech Personalized cancer treatments known as CAR–T cells (chimeric antigen receptor T cells) have dominated the headlines lately, thanks to Novartis' tisagenlecleucel, which won an early approval from the FDA for the treatment of leukemia on Aug. 30. 'It's a new era for cancer care': US clears first gene therapy for aggressive childhood leukemia |
